Emicizumab is a bispecific monoclonal antibody that binds to both the activated coagulation factor IX and to factor X. Emicizumab has been used in the management and treatment of hemophilia A.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.